Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Cogent Biosciences, Inc.NASDAQ: COGT
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $17.11M rose 76.1% year over year, ahead of the +50.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +76.1% holds above the trailing-twelve-month pace of +50.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 46.08M USD
- Year-over-year change
- +16.0%
- 4-year CAGR
- +40.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.08M | +16.0% |
| FY2024 | 2024-12-31 | 39.74M | +29.8% |
| FY2023 | 2023-12-31 | 30.62M | +66.7% |
| FY2022 | 2022-12-31 | 18.37M | +57.2% |
| FY2021 | 2021-12-31 | 11.69M | — |
Stock-Based Compensation vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's LTM Jun 2026 stock-based compensation of $60.37M is the 3rd largest of the 10 companies compared; the peer median is $49.18M.
- Its year-over-year change of +50.7% is the 4th highest of 10, against a peer median of +13.4%.
- Over three fiscal years its annual growth of +35.9% compares with a peer median of +22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.88M | -31.7% | +9.8% | 3.2% | |
| LTM Jun 2026 | $63M | -6.0% | -2.6% | 53.8% | |
| LTM Jun 2026 | $60.37M | +50.7% | +35.9% | — | |
| LTM Sep 2026 | $58.58M | +109.9% | +22.9% | — | |
| LTM Mar 2026 | $50.41M | +30.4% | +58.3% | 22.4% | |
| LTM Mar 2026 | $49.18M | +10.5% | +43.7% | 22.6% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Mar 2026 | $37.68M | +13.4% | +12.1% | 52.6% | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
| LTM Mar 2026 | $15.73M | +224.1% | +209.1% | — | |
| Peer median (excluding COGT) | $49.18M | +13.4% | +22.9% | 22.6% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.69M | 18.37M | 30.62M | 39.74M | 46.08M |
| Change in Working Capital | 2.02M | 751K | 11.44M | 11.6M | 8.01M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.75M | 2.36M | 4.81M | 1.36M | (2.51M) |
| Other Working Capital | (731K) | (1.61M) | 6.63M | 10.24M | 10.52M |
| Other Non-Cash Items | (343K) | (3.39M) | (6.87M) | (7.62M) | 5.82M |
| Operating Cash Flow | (58.76M) | (118.64M) | (153.62M) | (207.79M) | (264.44M) |
| Capital Expenditures | (1.72M) | (6.86M) | (2.8M) | (573K) | (1.55M) |
| Acquisitions (Net) | 0 | 117.86K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (177.86M) | (348.8M) | (255.6M) | (687.17M) |
| Sales of Investments | 0 | 60M | 253.78M | 294.45M | 289.2M |
| Other Investing Activities | 0 | (117.86K) | 0 | 0 | 0 |
| Investing Cash Flow | (1.72M) | (124.72M) | (97.82M) | 38.28M | (399.53M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 215.13M |
| Common Stock Issued | 38.01M | 161.95M | 161.82M | 213.34M | 712M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30K) | 1.61M | 0 | 1.12M | (48.9M) |
| Financing Cash Flow | 37.98M | 163.56M | 163.54M | 214.45M | 878.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.51M) | (79.8M) | (87.91M) | 44.94M | 214.26M |
| Free Cash Flow | (60.48M) | (125.5M) | (156.42M) | (208.36M) | (266M) |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.